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ABSTRACT
The Topo2a-dependent arrest is associated with
faithful segregation of sister chromatids and has
been identified as dysfunctional in numerous tu-
mour cell lines. This genome-protecting pathway
is poorly understood and its characterization is
of significant interest, potentially offering interven-
tional opportunities in relation to synthetic lethal be-
haviours in arrest-defective tumours. Using the cat-
alytic Topo2a inhibitor ICRF193, we have performed
a genome-wide siRNA screen in arrest-competent,
non-transformed cells, to identify genes essential for
this arrest mechanism. In addition, we have counter-
screened several DNA-damaging agents and demon-
strate that the Topo2a-dependent arrest is genet-
ically distinct from DNA damage checkpoints. We
identify the components of the SMC5/6 complex, in-
cluding the activity of the E3 SUMO ligase NSE2,
as non-redundant players that control the timing of
the Topo2a-dependent arrest in G2. We have inde-
pendently verified the NSE2 requirement in fibrob-
lasts from patients with germline mutations that
cause severely reduced levels of NSE2. Through
imaging Topo2a-dependent G2 arrested cells, an in-
creased interaction between Topo2a and NSE2 is ob-
served at PML bodies, which are known SUMOylation
hotspots. We demonstrate that Topo2a is SUMOy-
lated in an ICRF193-dependent manner by NSE2 at
a novel non-canonical site (K1520) and that K1520
sumoylation is required for chromosome segrega-
tion but not the G2 arrest.
INTRODUCTION
Cell cycle checkpoints delay progression if aberrant or in-
complete cell cycle events such as damaged or incompletely
replicated DNA are detected, thereby providing time for the
cell to resolve the problem (1,2). These are critical for the
precise inheritance of the parental genome, with defective
checkpoints being a hallmark of cancer cells contributing
to genetic instability and malignant transformation (2–4).
An intriguing but poorly understood cell cycle arrest is the
Topo2a-dependent arrest in G2, which has often been re-
ferred to as a decatenation checkpoint (5). Topo2a itself is
known to be required for this G2 arrest (6,7) and although it
is established that there is increased catenation consequent
to inhibition (8) it is not known whether catenation as such
is being sensed by cells. Moreover, this arrest has not for-
mally been identified as a bona fide cell cycle checkpoint in-
volving sensors, transducers and effectors, so we will refer
to it here as a Topo2a-dependent G2 arrest.
The Topo2a-dependent G2 arrest can be studied using
the tool compound ICRF193, a catalytic Topo2 inhibitor
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that prevents the enzyme release from DNA after DNA
double-strand break religation (9). By contrast, the so-
called Topo2 poisons such as etoposide stabilize the co-
valent enzyme–DNA complex prior to the religation step
in the catalytic cycle and are hence associated with dou-
ble strand breaks, typically triggering a DNA damage re-
sponse. The dysfunction of the Topo2a-dependent arrest
in a plethora of transformed cell lines (8,10–12) questions
the selective pressures exerted on the unknown mechanisms
that generate this arrest and also highlights the clinical po-
tential of the downstream failsafe pathway(s) as targets for
chemotherapy. These both prescribe a more detailed un-
derstanding of the genes involved in this G2 arrest and
their possible dysfunction in cancer. We therefore designed a
genome-wide siRNA screen to identify genes that are nec-
essary to arrest cell cycle progression under conditions of
compromised Topo2a activity using the catalytic inhibitor
ICRF193. Previous studies are limited because they pre-
dominantly identified putative players using transformed
cell lines (5,6,13–16). Given the various cell cycle abnormal-
ities associated with cancer cell lines, the present study was
designed to characterize the non-redundant requirements
for the Topo2a-dependent G2 arrest in non-transformed
cells.
Here, we unequivocally show that the Topo2a-dependent
arrest is genetically distinguishable from the DNA dam-
age checkpoint using a multistep screening approach. The
validity of the screen is evident from the identification of
Topo2a itself, a known requirement for this arrest, and ad-
ditionally five of six subunits of the SMC5/6 complex as
strong hits. Subsequent studies, including the use of patient-
derived cells with severely reduced levels of NSE2, impli-
cated the SMC5/6 complex and its NSE2 SUMO E3 ligase
subunit in this arrest and resolution pathway. Mechanisti-
cally, we have determined that upon ICRF193 engagement
of a G2 arrest there is an increased interaction of Topo2a
with the SMC5/6 subunit NSE2 at PML bodies. We also
reveal Topo2a as a previously unrecognized target of the
NSE2 E3 SUMO ligase and go on to show that SUMOyla-
tion of Topo2a at a novel site, K1520, is required for chro-
mosome segregation, but not the Topo2a-dependent G2 ar-
rest. The evidence points to a G2 arrest mechanism dis-
tinct from DNA damage checkpoint controls that engages
genes previously characterized in other contexts, but for
which their action in determining G2 progression following
Topo2a inhibition has hitherto been unrecognized.
MATERIALS AND METHODS
Reagents
For a full list of reagents please see Supplementary Table
S1.
Cell lines
All cell lines were maintained at 37◦C. For cell line authenti-
cation, cell lines were mycoplasma screened, speciated and
STR profiled. The STR profile was cross referenced back
to any available published profile for the line in question.
If there was no published profile available, it was checked
against the Cell Services STP database of the Francis Crick
Institute to ensure that it gives a unique profile. Please see
Supplementary Table S2 for further information.
For cDNA transfection of Doxycycline-inducible U2OS
cell lines X-tremeGENE 9 (Sigma) was used according the
manufacturer’s instructions and selection was carried out
at a concentration of 0.2 mg/ml Hygromycin (Invitrogen).
To induce Topo2a-GFP expression cells were cultured with
Doxycycline (100 ng/ml) for 24 h prior to assay for asyn-
chronous populations or with the first thymidine block for
synchronous/synchronised populations. Stable RPE1 cell
lines were generated using Lipofectamine LTX (Invitrogen)
and stable H2170 cells were generated using Fugene accord-
ing to the manufacturer’s instructions and selection was car-
ried out at a concentration of 0.8 mg/ml G418 (Sigma).
RNAi screen and G2 arrest assay
RPE1 cells were reverse-transfected with the human siRNA
Smartpool siGenome library from Dharmacon in black 384
well plates in triplicate using Lullaby transfection reagent
[OZ Biosciences, 900cells/well, 0.1L Lullaby/well, 19nM
siRNA and a number of Xrd-384 liquid dispensers (Flu-
idX)]. After 55 h, cells were treated for 18 h (for drug
concentrations see table below). This treatment duration
was chosen as it was long enough to allow sufficient cells
to go through the cell cycle but short enough to not al-
low mitotic slippage. Cells were subsequently fixed with
Methanol/Acetic Acid (95/5) overnight at −20◦C. Cells
were rehydrated in PBS, blocked in 2.5% BSA in PBS
and stained using Cy5-conjugated MPM2 (Millipore) and
DAPI (Merck). Images were acquired and analyzed using
both an ArrayScan VTi-automated microscope (Cellomics;
image analysis using the Target activation Bioapplication)
and an Acumen Explorer eX3 laser scanning microplate cy-
tometer (TTPLabtech data analysis using the Cellista anal-
ysis package). For each well the mitotic index (MI) was de-
termined [(Number of MPM2 positive cells/total number
of cells) × 100] and for the primary screen a median z-score
was derived using plate normalization [(well value − plate
median)/plate Median Absolute Deviation]. For the valida-
tion screens z-score normalization is not appropriate as only
a subset of the population is being analysed, which are ex-
treme effectors from the primary screen. Therefore, results
are expressed as a percentage of control, derived as [(well
value/plate mean Risc-free well) × 100]. For clarity, the
logged normalized MI are plotted. Throughout the paper,
each data point from any screen represents the median of n
= 3 technical replicates of an individual siRNA pool. When
the arrest behaviour was assessed independent of the screen
at least six technical replicates were performed, the experi-
ment was repeated three times and the percentage of mitotic
cells was determined through normalization to 1 M Noco-
dazole only treatment. The same protocol was used for all
screening rounds and subsequent arrest assays. The follow-
ing criteria were used for hit selection:
Cell synchronization
Cells were synchronized in early S phase through perform-
ing a double thymidine block. Cells were cultured for 16 h in
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Screen Normalization Condition Cut-off Image acquisition
Primary screen z-score 3 M ICRF193 + 1 M
Nocodazole
MIICRF > 2.5 MIICRF > 2.5 ArrayScan Acumen
Cell number > –1.5 Acumen
POC* 3 M ICRF193 + 1 M
Nocodazole
MIICRF > 350 MIICRF > 200 ArrayScan Acumen
10 M Bleomycin +1 M
Nocodazole
MIBleo < 200 MIBleo < 200 ArrayScan Acumen
No drug MInodrug < 150 MInodrug < 200 ArrayScan Acumen
Deconvoluted screen POC 3 M ICRF193 + 1 M
Nocodazole
MIICRF > 150 ArrayScan
Extended counter-screen POC 3 M ICRF193 + 1 M
Nocodazole
MIICRF > 350 ArrayScan
10 M Bleomycin + 1 M
Nocodazole
MIICRF > 2*MIBleo ArrayScan
1 M Etoposide + 1 M
Nocodazole
MIICRF > 2*MIEtop ArrayScan
10 GY  -irradiation +1 M
Nocodazole
MIICRF > 2*MI -irrad ArrayScan
No drug MIICRF > 2*MInodrug ArrayScan
*POC: percentage of control
growth medium supplemented with 2.5 mM thymidine 6 h
after reverse transfection of the indicated siRNAs. Subse-
quently, they were washed and released into growth medium
for 6 h before an additional 16 h incubation with 2.5 mM
thymidine. Cells were then released into growth medium for
5 or 10 h (as indicated) before additional drug treatments,
allowing specific analysis of cells treated in G2.
Co-immunoprecipitation and Immunoblotting
Cells were lysed by sonication in ice-cold RIPA-buffer (1%
Triton X, 1% sodium deoxycholate, 0.1% SDS, 150 mM
NaCl, 1 mM EDTA, 50 mM TRIS pH 7.4) supplemented
with Complete EDTA-free Protease Inhibitor Cocktail
(Roche), 1 mM PMSF and where indicated 25 mM
iodoacetamide. Additionally, where indicated lysates were
treated with 0.02 U/ml Benzonase Nuclease supplemented
with 1 mM MgCl2 for 1 h at 4◦C. After centrifugation
(14 000g, 4◦C, 10min), the supernatant was incubated with
Topo2a-antibodies (Millipore) or SMC6-antibodies (Ab-
cam) bound to Dynabeads Protein G (Invitrogen) or with
HA-agarose beads (Sigma) for 2 h at 4◦C. Immunoprecip-
itated proteins were washed using RIPA buffer, eluted us-
ing LDS-sample buffer (Invitrogen) for 5 min at 95◦C, sepa-
rated by SDS-PAGE and transferred to PVDF membranes.
Membranes were blocked overnight in either 5% fat-free
milk dissolved in PBS + 0.1%Tween20 (PBST) for the fol-
lowing antibodies: mouse monoclonal anti-HA (Covance),
rabbit polyclonal anti-SMC6 (Abcam), mouse monoclonal
anti-Topo2a (Millipore), rabbit monoclonal anti-Topo2a
(Abcam), rabbit polyclonal anti-Topo2a (Topogen), mouse
anti-alpha tubulin (Sigma), or with 2.5% BSA in PBS for
probing with rabbit polyclonal anti-SUMO2/3 (Enzo) or
with Streptavidin-HRP (Sigma). Antibodies were subse-
quently detected using HRP-conjugated secondary anti-
rabbit and anti-mouse antibodies (GE Healthcare) and Lu-
minata HRP substrate (Millipore). A representative image
of at least three experiments is shown.
Flow cytometry
Cells were stained with either Aqua or Blue LIVE/DEAD™
Fixable Dead Cell Stains (ThermoFisher Scientific) accord-
ing to manufacturer’s instructions, prior to fixation in ice-
cold 70% ethanol. Subsequently cells were permeabilized
with 0.1% Triton X and stained at RT in the dark for
1 h with either anti-GFP (Abcam) followed by anti-rabbit
Alexa Fluor488 (Invitrogen) and anti-MPM2-Cy5 (Milli-
pore) or anti-MPM2-Cy5 (Millipore) alone. Samples were
then stained with 50 mg/ml propidium iodide (PI) with
100 g/ml RNaseA at RT in the dark for 30 min and left
at 4◦C overnight. Flow cytometry was conducted using an
LSR or Fortessa flow cytometer and acquisition software
FACSDiva (BD bioscience). FACS analysis was performed
using the FlowJo software and gating for Aqua or Blue
negative (live) cells, single cells with PI staining and, where
required, GFP gating was applied. Cell cycle distributions
were calculated using the integrated Watson-Pragmatic al-
gorithm.
RNA preparation and real-time PCR
RPE1 cells were transfected with siRNAs targeting SMC6
or non-targeting controls using Lullaby transfection
reagent. 56 h later, RNA was isolated from RPE1 cells
using the RNeasy®-Kit (Qiagen). Reverse transcription
and Real-time PCR was performed using QuantiTect
SYBR Green RT-PCR Kit and the Applied Biosystems
7500 Fast System Real-time cycler. Primers are described
in Supplementary Table S1. We analysed data using the
2−CT-method with GAPDH as internal standard. Gene
expression was normalized to gene expression in the con-
trol siRNA-transfected samples. Mean and S.D. of three
experiments were determined.
Immunofluorescence imaging
Cells were grown on 13 mm glass coverslips and pre-
extracted with 0.1% Triton X in PBS for 30 s (all ex-
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periments except for IF analysis of segregation errors us-
ing anti-PICH antibodies), fixed using 4% PFA in PBS
for 10 min, re-permeabilized using 0.1% Triton X in PBS
for 5 min and blocked in 2.5% BSA in PBS for 1 h.
The following primary antibodies were used: rabbit poly-
clonal anti-GFP (Abcam), rabbit polyclonal anti-PICH,
(Novus), rabbit monoclonal anti-PML-Alexa Fluor555
(Abcam), rabbit polyclonal anti-SMC6 (Abcam), rab-
bit polyclonal anti-SUMO2/3 (Enzo), mouse monoclonal
anti-Topoisomerase2a (Millipore), mouse monoclonal anti-
PML (Abcam). Primary antibodies were detected with
Alexa Fluor488, 555 or 647 conjugated secondary antibod-
ies (Life technologies). All coverslips were mounted using
ProLong Gold Diamond (Invitrogen). Images were taken
using an inverted or upright laser scanning confocal micro-
scope (Carl Zeiss LSM 780 or 880) equipped with a 40× or
63× Plan-APOCHROMAT DIC oil-immersion objective.
PLA
RPE1 cells were grown on 8 well chambered slides (Fal-
con). Cells were reverse transfected and drug treated as for
the RNAi screen and fixed as for immunofluorescent imag-
ing. Proximity ligation assays were conducted using a kit
(Sigma) as per manufacturer’s instructions.
IF image analysis
All immunofluorescence images were quantified using a
custom-built script and the commercial software package
MATLAB (MATLAB 2016a, MathWorks). The images
were first segmented through the DAPI channel to subse-
quently enable nuclear foci detection through a percentile
based intensity filter. Nuclear area was used when quanti-
fying the number of foci to prevent bias as a result of drug
treatment altering nuclear size. For colocalization quantifi-
cation, the identified foci were compared across the chan-
nels and the percentage that colocalized were identified. At
least 10 images were analysed and the mean and S.E.M. of
at least three experiments was quantified.
Chromosome spreads
For measurement of catenation, RPE1 cells were trans-
fected with siRNAs targeting SMC6 or non-targeting con-
trols using Lullaby transfection reagent. 48 h later, cells were
retransfected with the same siRNAs together with siSgo1
for 24 h, followed by 12 h treatment with 1 M Nocoda-
zole to collapse the mitotic spindle. Cells were collected by
shaking off the mitotic cells and resuspending them in a hy-
potonic solution of 75 mM KCl and incubation at 37◦C for
30 min to expand the cells. Cells were then resuspended in
3:1 methanol:acetic acid and fixed overnight at –20◦C. Cells
were then washed using 3:1 methanol:acetic acid and spread
onto clear slides by dropping from a height of 2 m. For as-
says where Topo2a was reintroduced, recombinant Topo2a
(1 U/ml, TopoGen) was added in the hypotonic step where
the cell membrane becomes hyperpermeable. The hypotonic
buffer used here contained 5 mM TRIS, pH 8.0, 75 mM
KCl, 10 mM MgCl2, 2 mM ATP, 0.5 mM dithiothreitol.
Catenation was determined as the percentage of catenated
sister chromatids per cell (n = 15) and the mean and S.E.M.
of three experiments was calculated. Representative images
are shown.
In vitro SUMOylation
SUMOylation assays were performed using a SUMOyla-
tion kit (Enzo) according to the manufacturer’s instruc-
tions. Where indicated, 15 ng of human purified Topo2a
(Topogen) or 100 ng of purified biotinylated peptides and
100 ng of NSE2-GST (Abnova), PIAS1-GST (Enzo) or
PIAS4-GST (Abnova) were added and the reaction was in-
cubated for 45 min at 37◦C.
SMC5/6 expression analysis in LUSC patients
RSEM normalized gene expression RNASEQ TCGA data
was downloaded from the FireHose website [https://gdac.
broadinstitute.org/]. Gene expression values were ranked
and the upper and lower pentile samples were used to draw
survival plots using the survival package (version 2.40.1) in
R (version 3.3.3). Statistical significance was tested using
the log-rank test.
Statistical analysis
For experiments where the data include more than two con-
ditions, a two-way analysis of variance (ANOVA) using
multiple comparisons was used, in all other cases an un-
paired t-test was used for analysis as indicated in figure leg-
ends. Statistical details of individual experiments are given
in the figure legends or Materials and Methods section.
Prism software (Graphpad) was used for all calculations.
For analysis of statistical significance of survival curves a
log-rank test was used. The level of statistical significance is
represented as follows: not significant (ns) = P > 0.05, *P
≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 and ****P ≤ 0.0001.
RESULTS
A genome-wide RNAi screen shows that the Topo2a-
dependent G2 arrest is mechanistically distinct from the DNA
damage checkpoint
To identify cell lines with a stringent ICRF193-imposed ar-
rest suitable for a genome-wide siRNA screen we interro-
gated a panel of cell lines for their response to ICRF193
and used the DNA damaging agent Bleomycin as a positive
control for a G2 arrest. As a readout of G2 arrest we moni-
tored the mitotic index (MI) upon treatment with increasing
drug concentrations of either ICRF193 or Bleomycin. Si-
multaneous addition of the microtubule antagonist Noco-
dazole was employed to trap arrest evading cells in mitosis
enabling their quantification by immunofluorescence (IF)
staining for the mitotic marker MPM2 (19). While the nor-
mal diploid cell line RPE1 and some cancer cell lines elicited
a robust arrest in response to either drug, multiple cancer
cell lines showed an impaired response to ICRF193 while
retaining a response to Bleomycin (Figure 1A). Of note in
arresting cells, Bleomycin but not ICRF193 caused a pro-
found increase of the DNA damage marker H2AX under
these conditions (Supplementary Figure S1A). Combined,
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Figure 1. A genome-wide RNAi screen shows that the Topo2a-dependent G2 arrest is mechanistically distinct from the DNA damage checkpoint and
requires the SMC5/6 complex. (A) Graphs showing the responses of the indicated asynchronous cell lines in response to increasing concentrations of
ICRF193 or Bleomycin for 24 h. The bypass of arrest population was blocked in mitosis by inclusion of 1 M Nocodazole and identified by staining for
MPM2, yielding a mitotic index (MI) score through automated IF analysis. Data are represented as mean ± S.D. of a representative experiment with eight
technical replicates, where the percentage of mitotic cells is normalized to the Nocodazole only treated control. n = 2–3. (B) Distribution of the normalized
MI of the genome-wide siRNA library. This data is also part of Supplementary Figure S1E. (C) Heat-map of the arrest abrogation effects of the ICRF193-
selected hits in an extended counter-screen with multiple distinct chromatin stresses (IR, ionising radiation; Bleo, bleomycin; Etop, etoposide). (D) The
predicted protein-protein interactions for the 48 deconvoluted hits were compiled from the STRING database (green). To this we added additional hits
from the primary screen, which were sequentially added in groups of ten based on their ranked z-scores (grey > light grey > white). An additional 30 genes
were added before reaching the enrichment score threshold for background noise, 1 × 10−8.
this suggests that distinct signalling pathways govern the
DNA damage checkpoint and the Topo2a-dependent G2
arrest. Based on these cell profiles we selected RPE1 cells
for a genome-wide siRNA screen. Using RPE1 cells we de-
termined that there was no loss of viability in the 18 h arrest
assay configured for the screen and further that the arrest
observed with ICRF193 was not influenced by Nocodazole
treatment. Reciprocally, we saw that ICRF193 does not sig-
nificantly affect the nocodazole block, which was required
to trap mitotic cells for G2 progression scoring.
Previously suggested effectors of the Topo2a-dependent
arrest such as BRCA1, WRN, MDC1, ATM, ATR and
Chk1 (5,6,13–16) were tested in RPE1 cells and none were
found to have a non-redundant function in this arrest (data
not shown and Supplementary Table S3). However, we
noted that the combined knock-down of ATM and ATR
elicited a profound arrest failure (Supplementary Figure
S1B), consistent with their inhibition by caffeine (5). This
combination knock-down was employed as a positive con-
trol for the screen, where a genome-wide siRNA library was
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screened for siRNAs that abrogated the ICRF193-induced
G2 arrest (Supplementary Figure S1C). A stringent screen-
ing procedure was adopted (Supplementary Figure S1D)
and candidate genes were selected on the basis of a signifi-
cant arrest bypass, represented as the MI score (see Meth-
ods for hit selection criteria). Toxic siRNAs were identified
by a decrease in the cell number and excluded from further
analysis. Internal validation of the screen was provided by
the fact that the previously identified arrest effector Topo2a
was a strong hit (Figure 1B).
From the primary screen 317 potential hits were taken
forward (Figure 1B, Supplementary Figure S1E and Sup-
plementary Table S3) and we performed a secondary screen
including further controls. 151 siRNAs (47.6%) repeated
under the same assay conditions and six siRNAs (1.9%)
were eliminated from subsequent analysis because they
caused significant mitotic accumulation without ICRF193
treatment (Supplementary Figure S2A and Supplemen-
tary Table S4). The effects of the 317 candidates on the
ICRF193-induced arrest were also validated in U2OS cells,
a different cell line with a robust Topo2a-dependent ar-
rest, (Supplementary Figure S2B and Supplementary Ta-
ble S4). In U2OS cells 115 siRNAs reproduced the effect
seen in RPE1 cells corresponding to 76.2% of the 151 re-
peated siRNAs. To investigate directly whether candidate
hits specifically regulated only the Topo2a-dependent arrest
we also implemented a counter-screen to interrogate the ef-
fect of the 317 primary hit siRNAs on the ICRF193- and
the Bleomycin-induced arrests. Interestingly, 138 of the 151
repeated ICRF193 scoring siRNAs (92.7%) abrogated only
the ICRF193- and not the Bleomycin-induced G2 arrest
(Supplementary Figure S2C and Supplementary Table S4).
These results indicate that the implementation of the DNA
damage-induced G2 arrest and of the Topo2a-dependent
G2 arrest are at least in part mechanistically distinct.
The 138 ICRF193 arrest selective candidates were sub-
jected to siRNA deconvolution analysis, in which we indi-
vidually tested the four oligonucleotide duplexes compris-
ing the siRNA pools. The effect of an siRNA was consid-
ered likely to be on-target for a gene when two or more inde-
pendent siRNAs against this gene abrogated the arrest. This
was the case for 48 of the pools (35%) (Supplementary Fig-
ure S2D, Supplementary Table S5). To further investigate
the notion that DNA damage and catalytic inhibition of
Topo2a activate molecularly distinct regulatory processes,
we repeated and extended the counter-screen including not
only Bleomycin but also two additional treatments: the
Topo2 poison Etoposide and  -irradiation. Here, 100 genes
consistently scored for ICRF193 and for none of the three
DNA damage-inducing treatments (Figure 1C, Supplemen-
tary Figure S2E, Supplementary Table S6), while all treat-
ments caused accumulation of cells in G2 (Supplementary
Figure S2F). These results corroborate the conclusion that
the ICRF193-induced arrest is regulated through mecha-
nisms different from those involved in the DNA damage-
induced arrest.
Protein-protein interactions between the 48 deconvo-
luted hits (Supplementary Figure S2D, Supplementary Ta-
ble S5) were visualized using the STRING database (http:
//string-db.org/). To identify enriched networks and fur-
ther potential interactors, hit candidates from the primary
screen were sequentially added 10 at a time in a ranked z-
score dependent manner. An additional 30 genes were in-
cluded whilst maintaining statistical enrichment when com-
pared to an equivalent number of randomly selected genes.
The largest identified network contained Topo2a and the
SMC5/6 complex, with 12 nodes (genes) and 24 edges (in-
teractions) from the deconvoluted 48 hits. This was sub-
sequently enriched to 18 nodes and 35 edges with the ad-
ditional 30 proteins included (Figure 1D, Supplementary
Figure S2G). The connectivity and significant enrichment
of this network, alongside the predicted interaction with
Topo2a, identified the SMC5/6 complex as a strong can-
didate involved in controlling the timing of the Topo2a-
dependent G2 arrest.
The SMC5/6 complex regulates the Topo2a-dependent G2
arrest, sister chromatid disjunction and recruits NSE2 to
Topo2a
In mammalian cells, the SMC5/6 complex consists of the
SMC5/6 heterodimer and the non-SMC subunits NSE1–4
(Figure 2A). All subunits except for NSE4 scored in mul-
tiple screening rounds. NSE4, eliminated at the primary
screen stage, was retested and upon deconvolution of its
siRNA pool, two of the four oligos were seen to abro-
gate the ICRF193-induced arrest (Figure 2A). The decon-
volution of the siRNA pool targeting SMC6 confirmed the
ICRF193-induced override and the efficiency of the knock-
down, through both real-time PCR and western blot (WB)
(Supplementary Figure S3A). For further validation, we
engineered a squamous lung cancer cell line H2170 with
low SMC6 levels using a stably transfected shRNA, which
equally impaired the ICRF193-induced arrest while retain-
ing the DNA damage-induced G2 arrest (Supplementary
Figure S3B). Interestingly, examination of publicly available
patient data revealed a correlation between very low tran-
script levels of SMC5/6 and rapid disease progression in
squamous lung cancer patients, indicating an association of
complex depletion/loss with more aggressive tumours (Sup-
plementary Figure S3C).
To confirm the specific G2 phase requirement of the
SMC5/6 complex in response to compromised Topo2a ac-
tivity, U2OS cells were synchronized in early S phase and
the ICRF193-induced G2 arrest competency was analysed
in the presence and absence of SMC6. ICRF193 and noco-
dazole were administered when the cells reached G2 phase
(Supplementary Figure S3D) and we show that the G2 ar-
rest is abrogated when either SMC6 or ATM and ATR levels
are depleted (Figure 2B).
A recent publication suggested that loss of SMC6 causes
mislocalization of Topo2a on mitotic chromosomes, with
the presence of curly chromatids and distal enrichment (20).
We observed this in some cases when performing an siRNA-
mediated knockdown of SMC6, however we predominantly
saw a more dramatic effect with a loss of Topo2a from mi-
totic chromosomes in RPE1 cells (Supplementary Figure
S4A). This difference in observation compared to Gallego-
Paez et al. (20) might be explained by the different fixation
methods and antibodies used. Nevertheless, the conclusion
that part of the function of the SMC5/6 complex is to as-
sist the localization of Topo2a to chromosomes in mitosis
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Figure 2. The SMC5/6 complex regulates the Topo2a-dependent G2 arrest, sister chromatid disjunction and recruits NSE2 to Topo2a. (A) Asynchronous
RPE1 cells were transfected with the indicated siRNAs, treated with 3 M ICRF193 and 1 M Nocodazole for 18 h and the MI were quantified and
expressed as percentage of control (POC), in line with the Deconvoluted screen as described in the materials and methods (left panel). Data are represented
as mean ± S.D. and are compared to the average siATM+siATR positive control MI of 16.7% with an S.E.M of 0.61 from n = 48 triplicate repeats,
indicated by the dotted line. Schematic representation of the SMC5/6 complex (right panel). (B) U2OS cells were transfected with non-targeting control
(NTC), SMC6 or siATM+siATR siRNA, synchronized with a double thymidine block, released for 10 h and then treated with 3 M ICRF193 and 1 M
Nocodazole for a further 16 h. The mitotic index was determined through flow cytometry and staining for PI and MPM2. Data were normalized to 16 h of
1 M Nocodazole alone and represented as mean ± S.D. n = 3. (C) Confocal images of chromosome spreads of RPE1 cells transfected with the indicated
siRNAs with and without incubation of recombinant Topo2a in vitro. Bar graphs show quantification of SCI. Data are represented as mean ± S.E.M. (D)
IF staining of RPE1 cells for NSE2-GFP and Topo2a after treatment for 18 h with 3 M ICRF193 as indicated. White dotted boxes highlight enlarged
images displayed on the right. Scale bar = 10 m. (E) MATLAB-aided quantification, as described in the IF image analysis section of the Materials and
Methods, of PLA experiments using antibodies for Topo2a and NSE2-GFP. RPE1 cells were transfected with non-targeting control (NTC) or siSMC6 for
55 h and treated with 3 M ICRF193 for a further 18 h. Data are represented as mean ± S.E.M.
is clear. Employing a premature chromosome condensation
assay (21), we were able to extend this finding to G2-like
chromosomes (Supplementary Figure S4B). Knockdown of
SMC6 did not affect the expression levels of Topo2a (Sup-
plementary Figure S4C), suggesting that SMC5/6 is not re-
quired for its stability. Using co-immunoprecipitation we
detected an interaction between Topo2a and SMC6 (Sup-
plementary Figure S4D), as recently shown by Verver et al.
(22). To determine whether there was a direct interaction,
the lysates were treated with benzonase prior to immuno-
precipitation to remove chromatin and RNA, which might
otherwise bridge the proteins (data not shown). We saw
a small increase in this interaction with the addition of
ICRF193, but this did not reach statistical significance (P =
0.1359). Using proximity ligation assays (PLA), this inter-
action was confirmed implying that the SMC5/6 complex
and Topo2a interact closely (Supplementary Figure S4E),
within 40 nm. To investigate the functional importance of
this interaction we determined sister chromatid catenation
by a previously established assay that monitors sister chro-
matid intertwines (SCIs) by removal of centromeric cohe-
sion and viewing the chromosome formations (8). Briefly,
knockdown of Sgo1 causes loss of sister chromatid cohe-
sion, as Sgo1 is required to protect premature cleavage of
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centromeric cohesin in mitosis (23). After additional knock-
down of SMC6, sister chromatids appeared to have incom-
plete arm disjunction where they were often seen held to-
gether at their arms or giving a ‘closed-arm’ appearance.
Incubation with recombinant Topo2a reversed the observed
tethering phenotype indicating that the tetherings indeed re-
sult from catenation (Figure 2C).
In order to understand how the SMC5/6 complex might
promote Topo2a activity we then turned to the NSE2 sub-
unit of the SMC5/6 complex. We hypothesized, that in ad-
dition to the above described SMC6-dependent recruitment
of Topo2a, a possible signalling function could be elicited
by the E3 SUMO ligase NSE2 in arrest implementation
and/or sister chromatid resolution. To investigate a possi-
ble interaction between Topo2a and NSE2 we engineered
RPE1 cells stably expressing NSE2-GFP as several antibod-
ies tested were not able to detect endogenous NSE2. Us-
ing antibodies against Topo2a and GFP, colocalization of
Topo2a and NSE2 was revealed in discrete foci (Figure 2D),
which is in agreement with previous studies where NSE2
showed a punctate localization pattern (24). The high back-
ground observed in the NSE2-GFP signal precluded direct
quantification and complementary PLA experiments were
performed. Positive PLA foci further revealed that there
was an interaction between Topo2a and NSE2 and quantifi-
cation using MATLAB (as described in the Materials and
Methods) showed these discrete foci increased in response
to ICRF193, dependent upon the presence of SMC6. This
suggested Topo2a as a possible ICRF193-dependent sub-
strate of NSE2 (Figure 2E).
Topo2a colocalizes with PML bodies and SUMO2/3 foci
Topo2a foci have been described previously (14,25), but
the nature of these nuclear bodies is not known. Given the
colocalization of Topo2a with the SUMO E3 ligase NSE2,
we assessed whether these foci were PML bodies, whose
principal components are SUMO-modified and to which
NSE2 had previously been shown to localize (18,26). IF
analysis of RPE1 cells stained for Topo2a and PML, re-
vealed specific colocalization of Topo2a foci and PML bod-
ies (Figure 3A). MATLAB-aided quantification showed the
number of these PML and colocalized foci increased sig-
nificantly with ICRF193 treatment, but was not depen-
dent upon the presence of NSE2 (Figure 3B). Topo2a foci
were also found to colocalize with SUMO2/3 (Figure 3C)
and as reported elsewhere (27), we observed ICRF193-
induced SUMOylation of Topo2a (Figure 3D). We trans-
fected RPE1 cells with HA-tagged SUMO2, immunopre-
cipitated either Topo2a or HA-SUMO2 and then probed
with anti-HA and anti-Topo2a antibodies, revealing an en-
richment of higher-molecular weight SUMO2-conjugated
Topo2a in addition to unmodified Topo2a. SUMOylation
of Topo2a has been detected in budding yeast, Xenopus
egg extracts and human and murine cells during mitosis
(27–30). To test whether the observed SUMOylation was
cell cycle phase dependent or specifically associated with an
ICRF193 induced arrest, cells were treated with Bleomycin
to arrest them in G2. No increase in Topo2a SUMOyla-
tion was seen upon addition of Bleomycin, indicating that
the observed ICRF193-triggered SUMOylation is not due
to an arrest in G2 per se (Supplementary Figure S5A). As
expected, the abundance of SUMO2-modified Topo2a was
reduced when RPE1 cells were lysed in the absence of the
alkylating agent and isopeptidase inhibitor iodoacetamide
(IAA), which preserves SUMOylation through inhibiting
SUMO-specific proteases (Supplementary Figure S5A).
Consistent with our findings, comparison of the
ICRF193-selective hit list with a recently published PML-
interactome (31) revealed several shared components, most
of which are involved in SUMOylation, suggesting the
Topo2a-dependent G2 arrest is regulated by SUMOylation
at PML bodies (Figure 3E). This is further corroborated by
the finding that the only known SUMO E1 enzyme, SAE1,
was a strong hit in all screening rounds (Supplementary
Tables S3-S6).
Germline mutations demonstrate that NSE2 activity is re-
quired for the Topo2a-dependent G2 arrest
To address whether the ligase activity of NSE2 regulated
the Topo2a-dependent arrest and/or sister chromatid res-
olution, we initially used stable RPE1 cell lines expressing
siRNA-resistant NSE2wt-GFP or the ligase dead mutant
NSE2-H187A-GFP (32). The expression of NSE2wt-GFP
partially recovered the G2 arrest, however the NSE2 inac-
tive mutant exhibited a dominant negative behaviour where
it further increased the percentage of mitotic cells (Figure
4A) and also interfered with the ability to correct chromo-
some bridges. This is shown by an increase in DAPI-positive
chromatin bridges, an increase in lagging chromosomes and
an increase in PICH-positive ultrafine bridges (Figure 4B,
Supplementary Figure S5B), the last of these is a property
suggested to reflect catenation between sister centromeres
(33,34).
To validate independently whether NSE2 dysfunction in-
fluences these properties, we sought to test cells from pa-
tients with rare germline mutations in NSE2 resulting in
severely depressed levels of full-length NSE2 (17). A re-
markably consistent effect was seen with a compromised
Topo2a-dependent G2 arrest response (Figure 4C) and a
profound increase in segregation errors and PICH-positive
ultrafine bridges (Figure 4D, Supplementary Figure S5C).
Expression of wildtype NSE2 in these patient cells, but not
the ligase-dead NSE2 mutant, restored the functional arrest
corroborating its dependence on the ligase activity of NSE2
(Supplementary Figure S5D).
NSE2-mediated SUMOylation of Topo2a is essential for
Topo2a-dependent sister chromatid disjunction
Given the ICRF193-triggered increase of colocalized
Topo2a and NSE2 foci (Figure 2D, E), we determined
whether the ICRF193-induced SUMOylation of Topo2a
(Figure 3D) was dependent on NSE2. We analysed Topo2a
SUMOylation by PLA using antibodies against endoge-
nous Topo2a and SUMO2/3 in stable cell lines express-
ing NSE2wt or NSE2-H187A. Quantification of the PLA
foci confirmed not only an ICRF193-dependent increase of
Topo2a SUMOylation, but also established its dependence
on NSE2 (Figure 5A). Knockdown of SMC6 equally ab-
rogated the ICRF193-triggered SUMOylation of Topo2a
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Figure 3. Topo2a colocalizes with PML bodies and SUMO2/3. (A) IF staining of RPE1 cells for Topo2a and PML after 18 h treatment with 3 M
ICRF193 as indicated. (B) MATLAB-aided quantification, as described in the IF image analysis section of the Materials and Methods, of colocalization
between Topo2a (Millipore) and PML (abcam) in the presence and absence of NSE2. RPE1 cells were transfected with non-targeting control (NTC) or
siNSE2 for 48 h and subsequently treated with 3 M ICRF193 for 18 h where indicated. The percentages show the proportion of PML foci that were
positive for Topo2a. Data represents mean ± S.E.M. for n = 3. (C) IF staining of RPE1 cells for SUMO2/3 and Topo2a. Scale bar = 10 m. (D) RPE1
cells were transfected with HA-SUMO2, 24 h later treated with 3 M ICRF193 for 18 h as indicated before lysates were subjected to either anti-Topo2a
(left) or anti-HA (right) immunoprecipitation. Subsequent WB were performed for HA-SUMO and Topo2a. (E) Venn diagram showing overlap between
the ICRF193-selective hits and a recently identified PMLome (31). ATM and ATR are redundant players in the Topo2a-dependent G2 arrest.
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Figure 4. Germline mutations demonstrate that NSE2 activity is required for the Topo2a-dependent G2 arrest. (A) Quantification of MIs by automated IF
analysis of parental RPE1 cells and RPE1 cells stably expressing NSE2wt-GFP (NSE2 WT) or the ligase dead mutant NSE2H187A-GFP (NSE2 H187A).
Cells were transfected with the indicated siRNAs and treated with 3 M ICRF193 and 1 M Nocodazole for 18 h, fixed and stained for MPM2 and
DAPI. The siNSE2 transfection caused a significant increase (P < 0.0001) in mitotic cells compared to NTC (non-targeting control) for each cell line. Data
are normalized to 1 M Nocodazole alone and are represented as mean ± S.D. of a representative experiment of n = 3 with six technical replicates. (B)
RPE1 cells stably expressing siNSE2-resistant NSE2wt-GFP or the ligase dead mutant NSE2H187A-GFP transfected with the indicated siRNAs were
48 h later fixed and stained for PICH and DAPI. Quantification of segregation defects as defined by chromatin bridges or lagging chromosomes and
PICH-positive ultrafine bridges. Data are represented as mean ± S.D. A two-tailed t-test was used to analyse statistical significance. n = 3 with each 40
cells. (C) Quantification of MIs by FACS analysis of control and patient fibroblasts treated with 3 M ICRF193 and 1 M Nocodazole for 24 h, fixed and
stained for MPM2 and PI. Data are normalized to 1 M Nocodazole alone and are represented as mean ± S.D.. A two-tailed t-test was used to analyse
statistical significance. n = 3. This data is part of Supplementary Figure S5D. (D) Control and patient fibroblasts were fixed and stained for PICH and
DAPI. Quantification of segregation defects as in (B).
(Supplementary Figure S6A). Co-immunoprecipitation ex-
periments showed that NSE2-H187A still interacts with
SMC6 and hence the decreased SUMOylation is not due to
aberrant complex formation (Supplementary Figure S6B).
To test whether Topo2a is a direct substrate for SUMO
modification by NSE2, we investigated SUMOylation in
vitro using purified human Topo2a and recombinant NSE2
in the presence of SAE1 and UBC9. Topo2a SUMOy-
lation was analysed by immunoblotting for Topo2a and
SUMO2/3. As shown by the increase in SUMO2/3 con-
jugates of high molecular mass (>170kDa) (Figure 5B),
Topo2a was SUMOylated by NSE2, whereas no such mod-
ification was observed if NSE2 was replaced by the SUMO
E3 ligase PIAS1. We found that Topo2a was also SUMOy-
lated in vitro by PIAS4 (Supplementary Figure S6C), which
had been suggested previously to mediate SUMOylation of
Topo2a specifically in mitosis (27,29). NSE2 shows speci-
ficity in these reconstitution experiments as it did not pro-
mote the SUMOylation of RanGP1 (Supplementary Figure
S6D).
To address the functional importance of this NSE2-
mediated SUMOylation we sought to map the modifica-
tion site(s) on Topo2a. In order to do so, we took advan-
tage of the observation that two antibodies raised against
the very C-terminus of Topo2a (antibody #1 and #2) did
not recognize the slow-migrating bands of SUMOylated
Topo2a seen in response to ICRF193. These bands were
only recognized by antibody #3 that was raised against
full-length Topo2a (Supplementary Figures S7A, B). We
therefore speculated, that SUMOylation might compromise
the C-terminal epitope(s) recognized by these antibodies.
A peptide consisting of the last 18 amino acids of Topo2a
recognized by antibody #1 and #2 but not by antibody #3
contained three lysines presenting potential SUMOylation
sites (Supplementary Figure S7B). Indeed, branched pep-
tides, in which the five C-terminal amino acids of activated
SUMO2/3 were attached to each of the potential acceptor
lysines to mimic SUMOylation at these sites, interfered to
varying extents with the recognition by antibodies #1 and
#2 (Supplementary Figure S7C). We therefore considered
the possibility that all three lysines may become SUMOy-
lated and engineered U2OS FlpIn cells stably expressing
either Topo2awt-GFP or mutant Topo2aK1516,1517,1520R de-
noted Topo2a3KR-GFP. As anticipated this mutant was
not recognized by a C-terminus directed antibody but was
efficiently detected by the Topo2a-full-length or GFP recog-
nizing antibody (Supplementary Figure S7D). Topo2a3KR
mimicked expression of ligase-dead NSE2 causing an in-
crease in chromosome bridges (Figure 5C), but interestingly
this was not accompanied by an increase in PICH-positive
ultrafine bridges (Supplementary Figure S7E). To deter-
mine whether SUMOylation of Topo2a at the C-terminus
is important for Topo2a catalytic activity, we assessed sister
chromatid catenation using the chromosome spread assay.
As shown in Figure 5D, expression of Topo2a3KR caused a
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Figure 5. NSE2-mediated SUMOylation of Topo2a is essential for Topo2a-dependent sister chromatid disjunction. (A) MATLAB-based quantification
of PLA experiments using antibodies against Topo2a and SUMO2/3. RPE1 cells stably expressing NSE2wt-GFP or the ligase dead mutant NSE2H187A-
GFP were transfected with the indicated siRNAs and treated with 3 M ICRF193 for 18 h. Data are represented as mean ± S.E.M. (B) WB of in vitro
SUMOylation assays using recombinant human Topo2a, SAE1, UBC9, SUMO2 and SUMO3 incubated for 30 min at 37◦C with NSE2-GST or PIAS1-
GST as indicated. See also Supplementary Figure S6C and D. (C) U2OS FlpIn cells stably expressing inducible Topo2awt-GFP or Topo2a3KR-GFP
induced for 48 h with Doxycycline as indicated, fixed and stained with DAPI. Quantification of segregation defects as defined by chromatin bridges or
lagging chromosomes. Data are represented as mean ± S.D. n = 3 each with 50 cells. (D) U2OS FlpIn cells as in (C) induced for 24 h with Doxycycline and
transfected with siSGO1. The graph shows quantification of SCI in at least 28 cells. Data are represented as mean ± S.D. of a representative experiment.
n = 3.
significant increase in sister chromatid catenation indicating
compromised Topo2a activity of this mutant.
K1520 is a novel NSE2 SUMOylation site on Topo2a
To assess where NSE2 SUMOylates Topo2a, a biotinylated
peptide covering the last 20 amino acids at the C-terminus
of Topo2a (Topo2a1512–1531, denoted peptide 3K) was syn-
thesized alongside a modified peptide, in which all the
lysines were replaced by arginine (peptide 3R). A SUMOy-
lation assay in the presence of recombinant NSE2 was per-
formed and after separation by SDS-PAGE the sumoy-
lated, biotinylated peptides were identified by probing with
Streptavidin–HRP (note the free peptides were run off the
gel). As shown in Figure 6A, the 3K but not the 3R peptide
was efficiently SUMOylated by NSE2.
Interestingly, none of the lysines in this C-terminal
sequence conform to the minimal SUMOylation con-
sensus motif KxE (Figure 6B). However, an extended
SUMOylation motif, termed negatively charged amino
acid-dependent SUMOylation motif (NDSM) was recently
reported, suggesting an overrepresentation of acidic amino
acids downstream of a putative SUMOylation site with a
concentration at positions 3–6 (35). Comparing the NDSM
with the C-terminus of Topo2a, we hypothesized that
K1520 might be the preferred SUMOylation site as there
are multiple glutamates and aspartates at position 3, 4 and
6–9 downstream of K1520 (Figure 6B). Indeed, when us-
ing peptides in which pairs of lysines were replaced by argi-
nine a clear preference for SUMOylation of K1520 was
seen (Figure 6C). Subsequent generation of SUMOylation-
deficient single site mutants (Topo2aK1516R, Topo2aK1517R,
Topo2aK1520R) confirmed that only the K1520R mutation
phenocopies the segregation defect seen in the Topo2a3R
mutant (Figure 6D). These findings identify a novel, non-
canonical SUMOylation site in Topo2a that is modified in
response to compromised Topo2a activity.
Given that NSE2 and its E3 ligase activity are essential
to implement the Topo2a-dependent G2 arrest (Figures 2A
and 4A), we assessed whether the novel NSE2-mediated
SUMOylation site K1520 was also required for this arrest
mechanism. In polyclonal populations of synchronized G2
arrest competent U2OS cells, inducible expression of ei-
ther Topo2awt-GFP or Topo2aK1520R in combination with
siRNA mediated knockdown of endogenous Topo2a fully
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Figure 6. K1520 is a novel NSE2 SUMOylation site on Topo2a. (A) WB of in vitro SUMOylation assays using purified peptides as indicated and SAE1,
UBC9, SUMO2 and SUMO3 incubated for 45 min at 37◦C with NSE2-GST. The two bands on the SUMO2/3 blot correspond to SUMO2 and SUMO3,
which have different molecular weights. Only SUMOylated peptides are large enough to be retained on the SDS-PAGE gel, for transfer and detection by
streptavidin-HRP. (B) Comparison of the minimal and the extended SUMO-consensus (NDSM) site with the C-terminus of Topo2a, where  represents
an amino acid with an alipathic side chain and Ç represents a negatively charged amino acid. (C) Peptide SUMOylation in vitro as in (A). (D) U2OS FlpIn
cells stably expressing Doxycycline-inducible GFP-tagged Topo2a, Topo2aK1516R, Topo2aK1517R, Topo2aK1520R or Topo2a3KR induced for 48 h with
Doxycycline as indicated, fixed and stained with DAPI. Quantification of segregation defects as defined by chromatin bridges and lagging chromosomes.
Data are represented as mean ± S.D. n = 3 each with 30 cells. (E) U2OS FlpIn cells stably expressing doxycycline-inducible GFP-tagged Topo2a WT or
Topo2aK1520R were induced for 48 h with Doxycycline and transfected with siRNAs as indicated. Cells were synchronized by a double thymidine block
and 5 h after release were treated for 24 h with 3 M ICRF193 and 1 M Nocodazole. After fixation cells were stained for GFP, MPM2 and PI. Data are
normalized to 1 M Nocodazole alone and doxycycline induced cells were gated for a GFP positive and negative population, where there were over 1000
GFP positive cells, per condition in each experiment. Data are represented as mean ± S.D. n = 3.
recovered the ICRF193 induced G2 arrest (Figure 6E).
Sorted cells induced but not expressing Topo2a-GFP within
these polyclonal populations were unable to recover the G2
arrest providing an internal control to the observed rescue.
This indicates that there are both arrest and resolution sig-
nals emanating from NSE2 E3 SUMO ligase activity as part
of the SMC5/6 complex, with only the latter signal being
relayed by K1520 SUMOylation of Topo2a.
DISCUSSION
Topo2a-mediated resolution of sister chromatid intertwin-
ings is crucial for correct chromosome segregation and thus
genetic integrity. Our analysis of the Topo2a-dependent ar-
rest and reports by others (8,10,12,36) show that this arrest
is frequently attenuated or inactivated in cancer cells, sug-
gesting caution should be exercised when drawing conclu-
sions about the associated mechanisms operating in trans-
formed cells. There is however a need for a deeper under-
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standing of this arrest mechanism since this might provide
opportunities for therapeutic intervention, through target-
ing the emergent failsafe pathways (8). Here, we set out
to characterize the non-redundant genetic requirements for
the Topo2a-dependent G2 arrest in non-transformed cells
using an unbiased siRNA screen.
Previous studies implicated BRCA1, WRN, MDC1,
ATM, ATR, Chk1 and Topo2a as players in this ICRF193-
induced arrest (5,6,13–16). The present study confirms the
involvement of Topo2a as well as of ATM+ATR (identi-
fied as redundant players in pre-screening studies). How-
ever, in both the primary screen as well as when tested inde-
pendently, we failed to see an impact on G2 arrest in these
normal epithelial cells upon loss of BRCA1, Chk1, WRN
or MDC1 using siRNA-mediated knockdown. Of note, al-
most all of the studies describing these putative arrest play-
ers used transformed cells, more precisely DT40 (13) and
HeLa cells (6,14), which both have an attenuated response
to ICRF193 (16). This may indicate the action of redun-
dant functions, wherein components emerge as essential in
transformed somatic variants with compromised redundant
pathways. However, we do not exclude the possibility that
insufficient knockdown or differences in experimental setup
as highlighted by Bower et al. might explain these discrep-
ancies (16).
The family of SMC proteins, which comprises SMC1/3
(Cohesin), SMC2/4 (Condensin) and SMC5/6, play key
roles in the maintenance of genome integrity through
their function in DNA replication, segregation and repair.
Whereas the functions of Cohesin and Condensin are well
established, it has proven difficult to ascertain how the
SMC5/6 complex safeguards chromosome stability (37–
39). Several groups have shown that the complex has a role
in DNA repair through homologous recombination (HR)
and that it resolves or prevents aberrant recombination in-
termediates. However, the consensus is that the SMC5/6
complex is likely to have additional functions due to its
essential requirement in yeast, where other recombination
proteins are dispensable for survival (37,39–41). Indicative
of distinctive, hitherto undefined actions for this complex
beyond DNA repair and stalled replication fork resolution,
cell cycle regulated alleles restricting expression of SMC5/6
components revealed that the complex is essential in G2/M
but not in S-phase (42).
It has been speculated that the SMC5/6 complex con-
centrates around different types of joint molecules, such as
SCI, stalled forks and DNA repair intermediates, and re-
cruits complexes involved in their resolution (43). Murine
and human cells depleted of SMC5 or SMC6 accumulate
chromatid-linking anaphase bridges (20,44). Also, Verver
et al. observed that NSE2 null cells showed reduced sur-
vival upon treatment with Etoposide and that SMC6 inter-
acted with Topo2. Combining these results, they hypothe-
sized that NSE2 helps resolve topological stress (22). An el-
egant study in budding yeast concluded that SMC5/6 pos-
sibly associates with SCIs and facilitates their resolution
(45,46). By contrast, Kanno et al. suggested that SMC5/6
sequesters these catenanes behind the fork thereby facilitat-
ing fork rotation and resolution of superhelical tension (47).
This finding is however inconsistent with the hallmark of
segregation problems for the knockdown phenotype, which
indicates a function for SMC5/6 in the resolution of SCI.
Moreover, SMC5/6 and NSE2 hypomorphs are syntheti-
cally lethal with mutants of Topo2 (48), which is not essen-
tial for the resolution of supercoils but only for the resolu-
tion of SCI (45).
Here, we uncover an essential role for the SMC5/6 com-
plex in the Topo2a-dependent G2 arrest and in sister chro-
matid resolution. On ICRF193-induced G2 arrest we show
increased interaction of Topo2a and the SMC5/6 subunit
NSE2 at PML bodies, which are known nuclear SUMOy-
lation hotspots that have previously been implicated in the
response to cellular stress (31,49). We find that although
NSE2 is not required for Topo2a localization at PML bod-
ies, its E3 SUMO ligase activity is crucial to yield a Topo2a
and SUMO2/3 proximity signal. This observation, along-
side the finding that NSE2 supports Topo2a SUMOyla-
tion in vitro leads us to conclude that NSE2 SUMOylates
Topo2a at PML bodies in an ICRF193-dependent manner.
We map the NSE2-dependent SUMOylation to a previously
unrecognized, non-canonical site, K1520, on Topo2a.
We, and others, show Topo2a localization on chro-
mosomes is dependent on the SMC5/6 complex (20),
yet we demonstrate SMC5/6 loss does not cause a pro-
longed ICRF193-induced G2 arrest accompanying de-
creased chromatin-associated Topo2a activity. Instead, the
SMC5/6 complex is essential for G2 arrest implementation
and cells expressing ligase-dead NSE2 or Topo2a lacking
the C-terminal SUMO acceptor site K1520 have impaired
chromosome segregation reminiscent of catalytic Topo2a
inhibition (50). These observations are consistent with the
requirement for Topo2a itself in this arrest and with sev-
eral recent studies that show the C-terminus of Topo2a is
particularly important for the regulation of the Topo2a-
dependent arrest in yeast and human cells (6,7,51). Fur-
thermore, it is also in agreement with its previously pro-
posed requirement for faithful chromosome segregation in
drosophila (52).
The SUMO pathway has emerged as an important de-
terminant of genome stability but the underlying molec-
ular mechanisms, acceptor residues and involved E3 lig-
ases have proved difficult to define (53,54). SUMOylation
of Topo2 was detected in mitotic extracts from yeast, xeno-
pus egg extracts (XEE) and in murine embryo fibroblasts
(MEFs). The combined evidence strongly suggests Topo2
SUMOylation to be important for chromosome segrega-
tion (28,30,55,56). In XEE the E3 ligase was identified
as PIAS4 and acceptor residues were reported as K660,
K1235, K1276 and K1298, however mutation of these did
not completely block SUMOylation of Topo2 so addi-
tional sites must exist. Furthermore, PIAS4 was not shown
to SUMOylate Topo2a directly in human cells (57) and
PIAS4-/- mice have been found to be devoid of any overt
phenotypes, whereas mice with low amounts of the E3 lig-
ase RanBP2 developed severe aneuploidy (30). In line with
this, RanBP2 was identified as critical for the SUMOyla-
tion of Topo2a at unidentified acceptor residues, but only
in mitotic MEFs (57). Therefore, this questions the identity
of the ligase involved in interphase. Interestingly, RanBP2
hypomorphic mice are prone to spontaneous tumours, as
observed for mice with reduced expression of NSE2 (24).
NSE2 heterozygous MEFs also presented signs of improper
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chromosome segregation such as micronuclei and polynu-
cleated cells, but did not have major deficiencies in DNA
repair or replication.
A recent report that characterized patients present-
ing reduced levels of NSE2 due to compound heterozy-
gous frameshift mutations demonstrated that expression of
NSE2 wt, but not an NSE2 ligase-dead mutant, restored
nuclear abnormalities such as micronuclei and nucleoplas-
mic bridges (17). Here, we show that fibroblasts from these
patients also exhibit a defective Topo2a-dependent G2 ar-
rest and a dramatic increase in DAPI and PICH-positive
anaphase bridges indicating reduced Topo2a functional-
ity. In a previous study, knock-in mice with mutations that
reduce/inactivate the SUMO ligase activity of NSE2 were
shown to be physiologically normal (24). However, residual
ligase activity was detected for the ‘ligase dead’ mutant pro-
tein (24), which may have been sufficient to sustain Topo2
function. Furthermore, unlike many ubiquitin E2 enzymes,
UBC9 interacts with the SUMO modification consensus
sites in target proteins directly, such that SUMO conjuga-
tion can occur without E3 enzymes in the presence of high
concentrations of UBC9 (29). The elevation of local UBC9
concentrations at PML bodies together with partially ac-
tive NSE2 might be sufficient to maintain Topo2 SUMOy-
lation levels. It is also possible that in mice other PIAS fam-
ily members can compensate for the absence of NSE2 to
a greater extent than seems to be the case in humans. In
yeast, the mild phenotype of NSE2 SUMOylation-deficient
strains is greatly exacerbated upon deletion of additional
SUMO ligases (24).
Despite the requirement of Topo2a, NSE2 and its E3 lig-
ase activity for the implementation of the G2 arrest mecha-
nism, we find the NSE2-mediated SUMOylation of Topo2a
at K1520 is not essential to prevent mitotic progression but
is important for sister chromatid resolution. We can con-
clude that there must be additional SUMOylation targets
of NSE2 in response to compromised Topo2a activity that
mediate the G2 arrest and that the SUMOylation of K1520
is required as part of a distinct resolution pathway.
Using a well validated screen, the present report has iden-
tified a wealth of non-redundant players in the operation
of the Topo2a-dependent G2 arrest, among them the mul-
tifunctional SMC5/6 complex that includes the E3 ligase
NSE2. We have demonstrated that NSE2 is a critical reg-
ulator in response to compromised Topo2a activity and
that its ligase activity is required for a functional G2 ar-
rest. Furthermore, we identified Topo2a as a novel target
of NSE2 and reveal a non-canonical SUMOylation site re-
quired for efficient sister chromatid resolution. Although
further mechanistic details are yet to be identified from the
fruits of this genome-wide screen, the results here provide
a significant advance in our understanding of the biologi-
cal functions of the SMC5/6 complex. Furthermore, it has
provided opportunities to determine how the SMC5/6 as-
sociated functions and those exerted by other hits interact
to deliver an arrest, resolution and exit from this enigmatic,
genome protecting, control point.
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